MECP2 and Rett syndrome: The reduction of GluN2A expression in Mecp2-KO mice alleviates the decline in visual function, suggesting that targeting NMDA subunit composition might provide feasible therapeutic approaches for Rett syndrome and HIPK2 may represent a strong candidate.